ADDvise Group AB (publ) to redeem its outstanding up to SEK 240,000,000 senior secured callable bonds with ISIN SE0010298166
We refer to the outstanding up to SEK 240,000,000 senior secured callable bonds issued by ADDvise Group AB (publ) (the "Company") with ISIN: SE0010298166 (the "Bonds") and to the terms and conditions of the Bonds (the "Terms and Conditions").
Reference is further made to a call notice dated 21 May 2021, in which the Company informed the holders of the Bonds that it exercises its option to redeem all outstanding Bonds in full pursuant to Clause 8.3 (Voluntary total redemption (call option)) of the Terms and Conditions (the "Call Notice"), on 18 June 2021 (the "Redemption Date"). The Company's obligation to redeem the Bonds on the Redemption Date is conditioned upon the Company issuing senior secured floating rate bonds on terms that are acceptable for the Company (the "New Bonds") and fulfilling the conditions precedent for disbursement of the net proceeds from the issue of the New Bonds which are, among other things, to be applied towards financing the redemption of the Bonds (the "Financing Condition").
The Company hereby confirms that the Financing Condition will be fulfilled and will redeem the outstanding Bonds on the Redemption Date in accordance with the Call Notice.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, [email protected], is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.
Spago Nanomedical utser Paul Hargreaves till Chief Development Officer
Rekryteringen av Paul Hargreaves som CDO är ett viktigt steg för Spago Nanomedical nu när bolaget fortsätter att göra framsteg med sin unika projektportfölj, där Tumorad®med produktkandidaten SN201 avancerar i snabb takt mot kliniska studier, vilket kan g...
Spago Nanomedical appoints Paul Hargreaves as Chief Development Officer
The appointment of Paul Hargreaves as CDO marks an important step for Spago Nanomedical as the company continues to make progress with its unique project portfolio, with the Tumorad® candidate drug SN201 rapidly advancing towards clinical trials. This is an opportunity to provide potential treat...
Nanoform and Boehringer Ingelheim execute master services agreement
Christian Jones, CCO of Nanoform, commented: “Wider uptake of the latest technological innovations is essential to address the low success rates for new drug candidates in Pharma. We are delighted to collaborate with Boehringer Ingelheim to evaluate how our proprietary CESS® platform can help more n...
Sista dag för handel med Nanexa BTA den 2 augusti 2021 och ombokning till aktier
Om Nanexa AB (publ)Nanexa AB är ett nanoteknologiskt drug delivery-företag fokuserat på utvecklingen av PharmaShell®, ett nytt och banbrytande drug delivery-system med stor potential inom ett flertal substanstyper och indikationsområden. Inom ramen för PharmaShell® utvecklar Nanexa egna projekt och...